FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

TATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							. ,														
1. Name and Address of Reporting Person* Westphal Christoph H						2. Issuer Name and Ticker or Trading Symbol Flex Pharma, Inc. [FLKS]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner						
		-1													X					-	
(Lact)	(Fii	ret) (Middle)		2 0	2. Data of Farlingt Transportion (Marth/Day/Mart)								\dashv	X	Office	er (give title v)		Other (sp below)		
(Last)	`	,	wildule)			3. Date of Earliest Transaction (Month/Day/Year) 03/17/2016											President and CEO				
C/O FLEX PHARMA, INC.					03/17/2010									resident and GEO							
800 BOYLSTON STREET																					
(Street)					4. If	Ame	ndment	, Date o	of Origina	al File	d (Month/Da	ay/Year)		. Individ ine)	dual o	r Joint/Group	Filing (Ch	eck A	pplicable	
BOSTON	I M.	Α (2199												X	Form	filed by One	Reporting	Pers	on	
DOUTOI		· ·	72133													Form	m filed by More than One Reporting			orting	
(City)	(St	ate) (Zip)													Pers	on				
(5)												_									
		Tabl	e I - No	on-Deriv	ative	Sec	curitie	es Ac	quired	, Dis	posed o	f, or	Bene	eficia	ally O	wne	ed				
Date			2. Transa Date (Month/Da			2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a				l and 5) Se Be		ount of ities icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) (D)	or F	Price		Repor Transa (Instr.	ted action(s) 3 and 4)			(Instr. 4)	
Common	Stock			03/17/	2016				P		19,137	A	1 5	\$10.9	94(1)	2,8	344,460	I		See notes ⁽²⁾⁽³⁾	
Common	Stock			03/18/	2016				P		18,437	A	1 5	\$11.0	06(4)	2,8	862,897	I		See notes ⁽³⁾⁽⁵⁾	
Common Stock														3,925,248		D					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
Derivative Conversion Date Execuses (Month/Day/Year) if any							tion of		6. Date Exerci Expiration Dat (Month/Day/Ye		te	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			Deriva Securi		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owner Form: Direct or Indi (I) (Ins	(D) rect	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	or	ount nber res							

Explanation of Responses:

- 1. The price in Column 4 is a weighted average purchase price. The prices actually received ranged from \$10.53 to \$11.15. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
- 2. On March 17, 2016, Longwood Fund III, L.P. ("Longwood Fund III") purchased 19,137 shares of common stock of the Issuer (the "Common Shares"). Following such purchase, Longwood Fund III owned 147,196 Common Stock and Longwood Fund II, L.P. ("Longwood Fund II") owned 2,697,264 Common Shares.
- 3. Longwood Fund II GP, LLC is the ultimate General Partner of Longwood Fund III and Longwood Fund III GP, LLC is the ultimate General Partner of Longwood Fund III. Christoph Westphal, M.D., Ph.D., Richard Aldrich and Michelle Dipp, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood Fund II GP, LLC and Longwood Fund III GP, LLC, and, as such, may be deemed to have shared voting and dispositive power with respect to the Issuer's securities held by Longwood Fund II and Longwood Fund III (the "Longwood Shares"). Each of the Managers disclaims beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.
- 4. The price in Column 4 is a weighted average purchase price. The prices actually received ranged from \$10.92 to \$11.30. The reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
- 5. On March 18, 2016, Longwood Fund III purchased 18,437 Common Shares. Following such purchase, Longwood Fund III owned 165,633 Common Shares and Longwood Fund II owned 2,697,264 Common Share

Remarks:

/s/ Robert Hadfield, Attorney-** Signature of Reporting Person

03/21/2016

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.